Sentence examples for model for coronary from inspiring English sources

Dreher et al. (2015) focused on assessing the process of degradation of PLLA tubes in in-vivo tests as a model for coronary stent degradation.

Future studies to evaluate and quantify effects of clinically efficacious drugs with different mechanisms of action, (e.g. rapamycin [12], [23] or tranilast [24], [25]) in this model may prove useful to further validate the model for coronary restenosis and to identify positive controls for preclinical assessments of new pharmacological agents.

An appropriate model for coronary heart disease (CHD) could thus potentially allow users to simultaneously consider all the key issues when evaluating diverse options for intervention.

A previously developed state transition Markov cohort model for coronary heart disease (Martikainen et al., 2007; Peura et al., 2008) was enhanced by adding stroke and population components (Mar et al., 2008).

A previously validated epidemiological model for coronary heart disease was used to combine and analyse data on the uptake and effectiveness of specific cardiac treatments and changes in risk factors.

We previously reported that improvement in discrimination by glycated hemoglobin (HbA1c) over the Framingham prediction model for coronary heart disease was significant comparing C statistics but not using net reclassification improvement (22) and that even small improvements in discrimination were reflected in C statistics, largely mirrored by the integrated discrimination improvement (23).

Models for coronary artery disease also excluded people without validated coronary artery disease but with coronary artery disease identified in mortality data (n = 75).

Models for coronary artery disease did not control for hypercholesterolemia or hypertension because these outcomes were considered to potentially be in the causal pathway.

Models for coronary artery disease excluded people who reported heart disease that was not validated coronary artery disease (597 reported coronary artery disease that was not validated, and 3,728 reported heart disease other than coronary artery disease).

Our methods are illustrated using case-cohort samples which have been randomly sampled from a full cohort, and risk prediction models for coronary heart disease (CHD, defined as first ever non-fatal myocardial infarction or coronary death).

These data prompted us to examine whether the DPP-4 inhibitor, linagliptin, can attenuate neointima formation after vascular injury, which is one of the experimental models for coronary restenosis after coronary angioplasty.